Non-Hodgkin Lymphoma Drugs Market By Drug Class (Chemotherapy, Monoclonal Antibodies, Antibody-Drug Conjugates, Bispecific Antibodies, CAR T-Cell Therapies, BTK Inhibitors, BCL-2 Inhibitors, Immunomodulatory Drugs, Corticosteroids), By Lymphoma Subtype (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Other B-Cell and T-Cell Lymphomas), By Treatment Line (First-Line, Second-Line, Relapsed/Refractory and Later-Line), By End User (Hospitals and Cancer Centers, Specialty Hematology/Oncology Clinics, CAR T-Cell Treatment Centers), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Non-Hodgkin Lymphoma Drugs Market: Targeted Therapy, Bispecific Antibodies and CAR-T Are Rewriting Treatment Sequencing

The Global Non-Hodgkin Lymphoma Drugs Market was valued at USD 20.40 billion in 2025 and is projected to reach USD 38.50 billion by 2032, expanding at a CAGR of 9.5% during 2026–2032.

 

The Non-Hodgkin Lymphoma Drugs Market includes medicines used to treat blood cancers affecting the lymphatic system. It is shifting from reliance on traditional chemotherapy and anti-CD20 drugs like R-CHOP and rituximab toward newer therapies such as antibody-drug conjugates, bispecific antibodies, BTK/BCL-2 inhibitors, and CAR-T cell therapies.

 

FDA-approved Non-Hodgkin Lymphoma therapies now span several targeted classes, reflecting a shift away from traditional chemotherapy toward precision immunotherapy. These include anti-CD20 antibodies such as rituximab and obinutuzumab (and biosimilars) that deplete B-cells, CD19 CAR T-cell therapies like Yescarta and Breyanzi that use engineered immune cells to attack cancer, and CD20×CD3 bispecific antibodies such as epcoritamab and glofitamab that redirect T-cells to tumor cells. Antibody-drug conjugates like polatuzumab vedotin and brentuximab vedotin deliver cytotoxic agents directly into lymphoma cells, while BTK inhibitors (acalabrutinib, zanubrutinib) and BCL-2 inhibitors (venetoclax, sonrotoclax) block key survival pathways. Immunomodulators such as lenalidomide further enhance immune response, together forming a treatment landscape focused on immune activation and targeted cancer cell killing rather than broad cytotoxic chemotherapy.

 

The global patient base for non-Hodgkin lymphoma is large and continues to grow. In 2024, there were about 562,793 new cases worldwide and 234,903 deaths, with the highest number of cases in Asia, followed by Europe and North America. Overall, around 1.72 million people are living within five years of diagnosis globally, showing that many patients require long-term care and treatment.

 

In the United States alone, there are expected to be about 79,320 new cases and 19,970 deaths in 2026. The disease also has a relatively good long-term outlook, with a five-year survival rate of about 74% for patients diagnosed between 2016 and 2022. Because many patients live longer and often need multiple lines of therapy, the treatment market extends far beyond just newly diagnosed cases.

 

R-CHOP Still Controls Treatment Volume, but Its Economic Role Is Changing

R-CHOP remains a major frontline treatment backbone for diffuse large B-cell lymphoma and other aggressive B-cell NHLs. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone established a treatment standard that newer therapies must either improve, supplement or replace. The continued presence of R-CHOP matters commercially because DLBCL is a major NHL subtype and frontline treatment captures the largest single treatment cohort before the population fragments according to response and relapse status. NCI continues to identify R-CHOP as an established chemoimmunotherapy platform while recognizing newer alternatives for selected patients.

The anti-CD20 component is, however, becoming increasingly commoditized. FDA lists Truxima, Ruxience and Riabni as biosimilars to Rituxan, increasing price competition around rituximab while maintaining broad availability of CD20-directed treatment. The implication for suppliers is important: clinical utilization of rituximab-based regimens can remain high even while branded value migrates toward the newer molecule added to the regimen. 

Polivy demonstrates how that value transfer can occur. FDA approved Roche/Genentech's polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin and prednisone—Pola-R-CHP—for previously untreated DLBCL or high-grade B-cell lymphoma with an IPI score of at least 2. The 879-patient POLARIX trial produced a two-year progression-free survival rate of 76.7% with Pola-R-CHP compared with 70.2% with R-CHOP, representing a 27% relative reduction in the risk of progression, relapse or death. Overall survival and complete-response differences were not statistically significant at the original analysis. 

Commercially, Polivy is significant because it moves a premium antibody-drug conjugate into the large frontline DLBCL population instead of reserving advanced biologic therapy for patients after repeated relapse. Roche continued to report Polivy as a contributor to U.S. pharmaceutical growth during the first half of 2026, indicating that the shift is translating from regulatory approval into commercial utilization.

 

Bendamustine-Based Therapy Remains Important in Indolent Lymphoma

Indolent NHL creates a different treatment economy because patients can remain in therapy pathways for extended periods and frequently receive multiple lines of treatment. Bendamustine plus rituximab remains an established regimen across indolent B-cell lymphoma and mantle cell lymphoma populations.

Five-year follow-up of the BRIGHT study found progression-free survival of 65.5% with bendamustine plus rituximab compared with 55.8% for R-CHOP/R-CVP, with a hazard ratio of 0.61. No significant overall-survival difference was demonstrated. 

New drugs are increasingly being placed on top of this mature regimen rather than replacing it completely. In January 2025, FDA approved AstraZeneca's Calquence (acalabrutinib) plus bendamustine and rituximab for previously untreated mantle cell lymphoma in adults ineligible for autologous stem-cell transplantation. Median progression-free survival in ECHO was 66.4 months with acalabrutinib plus BR versus 49.6 months with BR alone. 

This combination illustrates a major revenue mechanism in the NHL drugs market: inexpensive established chemotherapy remains the treatment base while differentiated targeted drugs capture incremental value by extending disease control.

 

CAR-T Is Taking Revenue Away From Conventional Salvage Treatment

Relapsed aggressive B-cell lymphoma historically generated substantial use of R-ICE, R-DHAP and similar salvage chemotherapy before autologous stem-cell transplantation. CAR T-cell therapy has disrupted that sequence, particularly for patients whose large B-cell lymphoma is refractory to frontline treatment or returns within 12 months.

Yescarta is FDA-approved for adults with large B-cell lymphoma refractory to first-line chemoimmunotherapy or relapsing within 12 months, in addition to its later-line LBCL and follicular lymphoma indications. Breyanzi has also established broad activity across large B-cell lymphoma and multiple indolent or relapsed B-cell lymphoma populations.

The competitive advantage is no longer confined to third-line disease. NCI recognizes CAR-T approaches including axicabtagene ciloleucel and lisocabtagene maraleucel as important alternatives to conventional salvage chemotherapy and transplant strategies in high-risk early-relapsing large B-cell lymphoma.

Bristol Myers Squibb's commercial performance provides direct evidence that this therapeutic shift is creating revenue. Breyanzi generated USD 484 million worldwide in Q2 2026, up 41% from USD 344 million a year earlier. First-half 2026 revenue reached USD 896 million compared with USD 607 million in the first half of 2025, a 48% increase. U.S. Breyanzi revenue reached USD 354 million during Q2, while international revenue reached USD 131 million.

Label expansion is widening the addressable population further. FDA approved Breyanzi for relapsed or refractory follicular lymphoma in 2024, where the pivotal efficacy population achieved a 95.7% overall response rate, and approved it for mantle cell lymphoma later that year. In December 2025, Breyanzi became the first CAR T-cell therapy approved in the United States for adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic treatment lines. 

 

Bispecific Antibodies Create an Off-the-Shelf Challenge to CAR-T

CD20×CD3 bispecific antibodies are becoming one of the most commercially important treatment classes in relapsed B-cell NHL because they provide T-cell-directed immunotherapy without patient-specific cell manufacturing.

Roche's Columvi (glofitamab) is FDA-approved for selected relapsed or refractory DLBCL and large B-cell lymphoma after at least two systemic therapies. Epkinly (epcoritamab) from Genmab and AbbVie competes in relapsed DLBCL and follicular lymphoma. In November 2025, FDA granted traditional approval to Epkinly monotherapy for relapsed or refractory follicular lymphoma after two or more systemic therapies and also approved epcoritamab with lenalidomide and rituximab for relapsed or refractory FL. 

The commercial advantage of the class is operational. CAR-T requires patient-cell collection, manufacturing and specialist treatment infrastructure. Bispecific antibodies can be produced and distributed as conventional biologic medicines. Cytokine release syndrome and early-dose monitoring still create treatment-center requirements—for example, FDA's Columvi information includes hospitalization requirements around initial step-up dosing under defined circumstances—but the products avoid personalized manufacturing. 

The competitive question is therefore shifting from whether T-cell-directed therapy works to which delivery model can reach a larger eligible population at an acceptable clinical and operational cost.

 

Oral Targeted Therapies Expand the Post-Relapse Opportunity

BTK inhibitors already changed treatment patterns in mantle cell lymphoma, while BCL-2 inhibition is opening another post-BTK treatment opportunity.

BeOne Medicines' Brukinsa (zanubrutinib) plus obinutuzumab received accelerated FDA approval in 2024 for relapsed or refractory follicular lymphoma after at least two prior systemic treatments. In the ROSEWOOD trial, the combination produced an overall response rate of 69% compared with 46% for obinutuzumab alone. 

The company added another NHL asset in May 2026 when FDA granted accelerated approval to Beqalzi (sonrotoclax) for adults with relapsed or refractory mantle cell lymphoma after at least two lines of treatment, including a BTK inhibitor. The approval directly establishes a commercially defined post-BTK population rather than forcing another targeted drug to compete for the same untreated patients. 

Combination competition is also increasing in follicular lymphoma. FDA approved Incyte's Monjuvi (tafasitamab) with lenalidomide and rituximab in June 2025 for relapsed or refractory follicular lymphoma. The randomized inMIND study enrolled 548 patients, giving another targeted combination access to a treatment setting already contested by bispecific antibodies, CAR-T, BTK-based combinations and established immunochemotherapy. 

Pfizer has expanded Adcetris beyond its established T-cell lymphoma presence. In February 2025, FDA approved brentuximab vedotin plus lenalidomide and rituximab for selected relapsed or refractory LBCL patients who are ineligible for autologous transplantation or CAR-T. Median overall survival was 13.8 months for the brentuximab combination versus 8.5 months for the comparator arm. 

 

North America: Leading Commercialization Region for Advanced NHL Therapy

North America has the strongest current commercialization environment for advanced NHL drugs. GLOBOCAN 2024 estimates 85,494 new NHL cases and 24,249 deaths in Northern America, while the United States alone is expected to record 79,320 new cases in 2026. Northern America also has approximately 294,708 people within five years of an NHL diagnosis, supporting a large population requiring surveillance, maintenance or subsequent treatment. The North America Non-Hodgkin Lymphoma drugs market is valued at approximately USD 3.1 billion in 2025 and is projected to reach around USD 5.8 billion by 2032, growing at a CAGR of 9.5%, accounting for an estimated ~15% share of global NHL incidence. 

North America is the leading commercialization region for NHL drugs, driven by early adoption of advanced therapies such as ADCs, bispecific antibodies, CAR-T, BTK combinations, and BCL-2 inhibitors like sonrotoclax. Regulatory and reimbursement support is strong, with the FDA removing CAR-T REMS requirements in 2025 and CMS continuing Medicare coverage for eligible CAR-T treatments. This has helped accelerate access to high-cost therapies. The region’s strength is reflected in Breyanzi, which generated USD 645 million in the U.S. out of USD 896 million globally in H1 2026 (around 72%). Overall, North America leads due to high diagnosis rates, early approvals, strong treatment infrastructure, and established reimbursement systems supporting rapid uptake of advanced therapies.

 

Europe: Large Patient Base and Broad Advanced-Therapy Availability

Europe accounted for approximately 128,816 new NHL cases, 48,616 deaths and 433,773 five-year prevalent cases in 2024, making it the second-largest regional patient pool after Asia.  The region represents ~22.9% of global cases, translating to an estimated market size of ~USD 4.67 billion in 2025, with a projected CAGR of ~9.4% in line with the global Non-Hodgkin Lymphoma Drugs Market growth trajectory.

European regulators have approved several advanced therapies that are reshaping B-cell lymphoma care, including Polivy for DLBCL, Breyanzi for multiple lymphoma types, Lunsumio for follicular lymphoma, and Tepkinly for relapsed or refractory DLBCL. This gives European clinicians access to CAR-T, antibody-drug conjugates, and bispecific antibodies. As a result, Europe is now a high-value competitive market where companies must show clear benefits over low-cost immunochemotherapy and navigate fragmented reimbursement systems, with added advantage for therapies that reduce hospital use and specialist care requirements.

 

Asia-Pacific: Largest Patient Pool Creates the Long-Term Expansion Opportunity

Asia contains the world's largest absolute NHL burden. GLOBOCAN 2024 estimates 250,711 new cases, 119,202 deaths and 727,120 five-year prevalent cases, representing 44.5% of global incidence and 50.7% of global NHL mortality. The region accounts for an estimated market size of ~USD 9.1 billion in 2025 and is projected to grow at a CAGR of ~9.5% during 2026–2032. 

The Asia-Pacific region represents a large but uneven opportunity for NHL therapies, with a patient base far exceeding current premium-treatment revenue. Countries like Japan already support advanced therapies such as CAR-T (e.g., Breyanzi), showing strong adoption in developed healthcare systems. However, across the wider region, access remains inconsistent due to differences in reimbursement, infrastructure, and affordability. As a result, high-income markets are adopting CAR-T, bispecific antibodies, and targeted therapies, while most patients in lower- and middle-income countries still rely on biosimilar rituximab, chemotherapy, and lower-cost targeted drugs.

 

Latin America, Middle East and Africa: Access Economics Shape Therapy Mix

Latin America & Caribbean accounted for ~7.6% share of global NHL incidence, with an estimated market size of ~USD 1.55 billion in 2025, and is projected to expand at a CAGR of ~9.5% through 2032. GLOBOCAN 2024 estimates approximately 42,721 NHL cases in Latin America and the Caribbean and 46,502 in Africa, compared with 18,495 and 21,802 deaths respectively. 

These regions provide meaningful patient demand but are less suited to immediate large-scale commercialization of individualized cell therapies than the United States, Western Europe or Japan. Generic chemotherapy, rituximab biosimilars and therapies with simpler administration requirements are therefore strategically important. Longer-term opportunity for bispecific antibodies and oral targeted agents could be stronger than for personalized CAR-T where manufacturing logistics and specialist hospitalization remain binding constraints.

 

Competitive Landscape: NHL Is Becoming a Multi-Platform Portfolio Battle

The competitive landscape of the Non-Hodgkin Lymphoma (NHL) drugs market is increasingly defined by diversified portfolios that span monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, CAR-T therapies, and targeted oral agents. Leading companies are no longer competing with single blockbuster drugs but are instead building multi-platform strategies that allow them to participate across different stages of the treatment pathway, from frontline therapy to relapsed and refractory disease settings.

Roche holds one of the most diversified competitive positions in the market, anchored by its established anti-CD20 franchise through Rituxan/MabThera and Gazyva/Gazyvaro, while also advancing into next-generation therapies with Polivy (ADC) and the bispecific antibodies Columvi and Lunsumio. This broad portfolio allows Roche to remain strongly positioned across both traditional immunochemotherapy standards and emerging targeted treatment approaches. Roche’s first-half 2026 results further highlighted Polivy as a meaningful contributor to U.S. growth, reinforcing the commercial momentum of its newer oncology assets.

Bristol Myers Squibb is pursuing a distinct strategy centered on a single CAR-T platform, Breyanzi, which is being expanded across multiple B-cell malignancies, including large B-cell lymphoma (LBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). This broad label expansion positions the company as a major force in the cellular therapy segment, with growing penetration into earlier lines of treatment. Breyanzi’s commercial performance reflects this momentum, with worldwide revenue increasing 41% year over year in Q2 2026, while international sales grew even faster in the first half of the year, reaching USD 250 million compared to USD 148 million in the prior-year period. (fda.gov)

Gilead/Kite continues to leverage Yescarta as a leading CAR-T therapy, particularly in early-relapse LBCL, while also extending its presence into follicular lymphoma. The company remains a dominant force in the CAR-T space, benefiting from strong clinical adoption in aggressive lymphoma settings.

AbbVie and Genmab are strengthening their position through Epkinly/Tepkinly, an off-the-shelf CD20×CD3 bispecific antibody that sits between conventional drug therapy and personalized cellular approaches. The November 2025 U.S. follicular lymphoma expansion further reinforced this strategy by enabling both monotherapy and combination use in an increasingly competitive relapsed setting, broadening its role across DLBCL and follicular lymphoma while providing a scalable alternative to CAR-T therapies. (fda.gov)

AstraZeneca and BeOne are increasingly competing in the oral targeted therapy space for mantle cell lymphoma. AstraZeneca is advancing Calquence into frontline use, including in transplant-ineligible patients, allowing access to a broader and earlier-stage patient population. In parallel, BeOne is strengthening its position across the treatment continuum with Brukinsa and the BCL-2 inhibitor sonrotoclax, targeting patients both prior to and following BTK inhibitor failure, thereby extending its reach across multiple lines of therapy. (fda.gov)

BeOne Medicines is pursuing a dual-platform strategy with Brukinsa (BTK inhibitor) and Beqalzi (BCL-2 inhibitor), targeting both follicular lymphoma and post-BTK mantle cell lymphoma. This positions the company to address sequential treatment needs across multiple disease stages, particularly in relapsed settings.

Incyte is strengthening its presence in B-cell malignancies through Monjuvi, a CD19-targeted therapy that is expanding from diffuse large B-cell lymphoma (DLBCL) into follicular lymphoma. The company is focusing on combination-based strategies to enhance efficacy and broaden clinical utility.

Pfizer maintains a strong position in the ADC segment through Adcetris, which is increasingly being used in CAR-T-ineligible LBCL patients. This allows Pfizer to participate in both traditional and emerging treatment pathways, particularly where cellular therapy is not feasible.

Overall, the competitive landscape is increasingly defined by multi-modality portfolios, with market success depending on a company’s ability to span multiple mechanisms of action and treatment lines rather than relying on a single drug class. As a result, competitive intensity is expected to rise most significantly in relapsed follicular lymphoma, mantle cell lymphoma following BTK inhibitor exposure, and early-relapsing large B-cell lymphoma, where several therapeutic platforms are now directly competing for the same patient populations.

 

Analyst Perspective: How Platform Therapies, Sequencing Control, and Line-of-Therapy Expansion Are Redefining Value in the NHL Drugs Market

The Non-Hodgkin Lymphoma drugs market is entering a phase where innovation is no longer defined by single-agent superiority but by system-level disruption across the entire treatment continuum. The most consequential shift is the transition from linear drug competition to ecosystem competition, where companies compete to anchor multiple decision points in a patient’s journey rather than a single line of therapy.

A key inflection is the collapse of traditional treatment sequencing boundaries. CAR-T therapies, bispecific antibodies, antibody-drug conjugates, and targeted oral agents are no longer confined to late-stage use. Instead, they are actively moving into frontline and early-relapse settings, compressing the historical advantage held by chemotherapy backbones such as R-CHOP and bendamustine-based regimens. This is fundamentally redefining how value is distributed across the market.

Another structural shift is the rise of “platform durability” as a competitive metric. The most successful assets are no longer those with peak efficacy in a single indication, but those capable of expanding across multiple lymphoma subtypes and treatment lines. CAR-T franchises like Breyanzi and Yescarta, and multi-indication biologic platforms from Roche, illustrate how lifecycle expansion is becoming more important than initial approval impact.

At the same time, the market is experiencing a delivery-model divergence. Personalized therapies such as CAR-T are creating high clinical depth but face manufacturing and access constraints, while bispecific antibodies and oral targeted therapies are gaining traction through scalability and ease of administration. This divergence is creating a dual-speed market: one driven by high-cost, high-efficacy individualized treatments and another driven by scalable, repeatable outpatient therapies.

Finally, the competitive frontier is shifting toward post-resistance segmentation, where therapies are increasingly designed for biologically defined subgroups such as post-BTK failure, CAR-T-ineligible patients, or early-relapsing high-risk disease. This segmentation is expanding the total addressable market not by increasing incidence, but by multiplying the number of treatable disease states within the same patient population.

Analyst Insight: The NHL therapeutics landscape is no longer a drug market—it is becoming a multi-platform sequencing economy, where long-term winners will be those capable of controlling successive treatment transitions rather than isolated clinical endpoints.

 

 

Non-Hodgkin Lymphoma Drugs Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 20.40 Billion
Revenue Forecast in 2032	USD 38.50 Billion
Overall Growth Rate	CAGR of 9.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Drug Class, By Lymphoma Subtype, By Treatment Line, By End User, By Geography
By Drug Class	Chemotherapy, Monoclonal Antibodies, Antibody-Drug Conjugates, Bispecific Antibodies, CAR T-Cell Therapies, BTK Inhibitors, BCL-2 Inhibitors, Immunomodulatory Drugs, Corticosteroids
By Lymphoma Subtype	Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Other B-Cell and T-Cell Lymphomas
By Treatment Line	First-Line, Second-Line, Relapsed/Refractory and Later-Line
By End User	Hospitals and Cancer Centers, Specialty Hematology/Oncology Clinics, CAR T-Cell Treatment Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising global NHL incidence, increasing adoption of targeted therapies and immunotherapies, expansion of CAR-T and bispecific antibody indications, growing demand for personalized oncology treatments, rising use of combination therapies across treatment lines
Customization Option	Available upon request